pharma · Chronic kidney disease · Advanced solid tumors
Bayer
Bayer AG
Bayer is a pharma organization headquartered in Leverkusen, DE. Primary therapeutic focus areas include Chronic kidney disease, Advanced solid tumors, Heart failure due to systemic left ventricular systolic dysfunction,
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE HQ
97,894 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE
- Employees
- 97,894
- Programs
- 47
- Drugs
- 62
- Patents
- 5
Eylea 114.3 mg/ml solution for injection
Approved · small molecule · Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME)
Eylea 114.3 mg/ml solution for injection for Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME) is a Approved program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).
Internal code 22578
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bayer AG
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME)
- Status
- active
- Trials
- 1